Glaxosmithkline Biologicals Sa

Novartis Ag

J. Craig Venter Institute

Novartis Vaccines & Diagnostics, Gmbh

Novartis Vaccines and Diagnostics Srl

Ospedale San Raffaele S.r.l.

Maria Scarselli

Vega Masignani

Guido Grandi

Mariagrazia Pizza

Rino Rappuoli

Claire M Fraser

Marirosa Mora

Herve Tettelin

Cesira Galeotti

Vincenzo Scarlato

John Telford

Erin Hickey

Giulio Ratti

Jeremy Petersen

J Craig Venter

Manuele Martinelli

Marzia Monica Giuliani

Nathalie Norais

Fabio Bagnoli

Luigi Fiaschi

Matthew Bottomley

Massimiliano Biagini

Enrico Malito

Ravi Pratap Narayan Mishra

Immaculada Margarit Y Ros

Giuliano Bensi

Maria Arico

Emiliano Chiarot

Guilio Ratti

Barbara Capecchi

Susan Barnett

Maurizio Comanducci

Indresh K Srivastava

Victoria A Sharma

Davide Serruto

Brunella Brunelli

Silvana Savino

Rosanna Leuzzi

Mariarosa Mora

Hervé Tettelin

Daniele Veggi

Danilo Gomes Moriel

Marco Soriani

Maria Aricò

Roberto Petracca

Gillian Douce

Craig Venter

Meera Unnikrishnan

Silvia Rossi Paccani

Beatrice Maria Arico

Maria Rosa Mora

Giulo Ratti

Jeremy D Peterson

Craig Ventor

Irene Bianconi

Alessandra Bragonzi

Beatriz Alcala′ Franco

Enzo Scalato

Laura Ciucchi

Federica Di Marcello

Beatriz Alcala' Franco

Ravi Mishra

Mazia Monica Giuliani

Mariagratia Pizza

Modified meningococcal fHbp polypeptides with increased stability.

Modified meningococcal fHbp polypeptides

The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing againstinfection.

Modified meningococcal FHBP polypeptides

The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant.

Adjuvanted combinations of meningococcal factor H binding proteins

The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence.

Combinations of meningococcal factor H binding proteins

The invention provides proteins from group B() and group A(), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Nucleic acids and proteins from streptococcus groups A and B

Mutant protein A of(SpA) with decreased affinity for the Fc&#x3b3; portion of human IgG is provided.

Mutant staphylococcal antigens

NTHI protein antigens have been identified and found to be conserved across severalpathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.

Antigens and antigen combinations

The invention provides proteins fromincluding amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.

[object Object]

An effectivevaccine may require several antigenic components, and so various combinations ofantigens are identified for use in immunisation. These polypeptides may optionally be used in combination withsaccharides.

An effectivevaccine may require one or several antigenic components, and so various antigens ofare identified for use in immunization. These polypeptides may optionally be used in combination with other nosocomial antigens.

The invention provides methods, proteins, nucleic acids and antibodies for preventing or treating ainfection in a mammal.

Clostridium difficile polypeptides as vaccine

Growing community of inventors

Siena, Italy

Maria Scarselli